Arrhythmias & electrophysiology
Safety and Efficacy of the Novel OmniaSecure Defibrillation Lead Through Long-Term Follow-Up: Final Results From the LEADR Trial
Authors' conclusion
The final results of the LEADR trial demonstrated 3-year term safety, efficacy, and reliability of the OmniaSecure lead, emphasizing the potential utility of this lead in a wide variety of patients.
Study context
- Population
- Patients with an indication for de novo ICD/CRT defibrillator643 (97.9%) successfully implanted
- Participants
- 657 patients
- Outcome
- Freedom from major study lead-related complications
- Follow-up
- 3 years
Methodological detailsprospective, multicentre
- Prospective
- Multicentre
Main finding
As reported in the abstract
Freedom from major study lead-related complications at 3 years
96.5%
Observational data: associations, not effects.
Further findings
Appropriate therapies (shock and ATP) · 3 years
- Patients receiving appropriate therapies
- 22.3%
- Antitachycardia pacing efficacy
- 75.4%
Pacing capture threshold, pacing impedance, R-wave amplitudes
- Remained stable throughout
Safety
- Inappropriate shock rate at 1 year
- 2.7%
- Inappropriate shock rate at 3 years
- 5.9%
Original publication
Safety and Efficacy of the Novel OmniaSecure Defibrillation Lead Through Long-Term Follow-Up: Final Results From the LEADR Trial. Circ Arrhythm Electrophysiol. Published 12 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →